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Abstract
Background/Aim: Neuropathy is the most common neurologic complication of HIV but is widely under-diagnosed in
resource-constrained settings. We aimed to identify tools that accurately distinguish individuals with moderate/severe
peripheral neuropathy and can be administered by non-physician healthcare workers (HCW) in resource-constrained
settings.
Methods: We enrolled a convenience sample of 30 HIV-infected outpatients from a Kenyan HIV-care clinic. A HCW
administered the Neuropathy Severity Score (NSS), Single Question Neuropathy Screen (Single-QNS), Subjective Peripheral
Neuropathy Screen (Subjective-PNS), and Brief Peripheral Neuropathy Screen (Brief-PNS). Monofilament, graduated tuning
fork, and two-point discrimination examinations were performed. Tools were validated against a neurologist’s clinical
assessment of moderate/severe neuropathy.
Results: The sample was 57% male, mean age 38.6 years, and mean CD4 count 324 cells/mL. Neurologist’s assessment
identified 20% (6/30) with moderate/severe neuropathy. Diagnostic utilities for moderate/severe neuropathy were: Single-
QNS - 83% sensitivity, 71% specificity; Subjective-PNS-total - 83% sensitivity, 83% specificity; Subjective-PNS-max and NSS -
67% sensitivity, 92% specificity; Brief-PNS - 0% sensitivity, 92% specificity; monofilament - 100% sensitivity, 88% specificity;
graduated tuning fork - 83% sensitivity, 88% specificity; two-point discrimination - 75% sensitivity, 58% specificity.
Conclusions: Pilot testing suggests Single-QNS, Subjective-PNS, and monofilament examination accurately identify HIV-
infected patients with moderate/severe neuropathy and may be useful diagnostic tools in resource-constrained settings.
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Introduction
Peripheral neuropathy is the most common neurologic compli-
cation of HIV but is widely under-recognized and under-treated in
resource-constrained settings.[1] Task-shifting, delegating health-
care tasks to less specialized healthcare workers, is common in many
such locations as a result of the scale-up of antiretroviral
programs.[2] Simple inexpensive diagnostic tools that can be
administered by non-physician healthcare workers may improve
recognition of neuropathy in resource-constrained settings.
Several screening tools and quantitative sensory testing (QST)
methods, including the monofilament, Rydel-Seiffer graduated
tuning fork, and two-point discriminator, have been shown to
accurately identify individuals with neuropathy.[3–8] However,
these tools have been almost exclusively validated in high-income
countries by specialized physicians. Furthermore, none includes a
functional status assessment which may be important to identify
individuals with a moderate to severe neuropathy in need of
intervention. Therefore, we developed the Neuropathy Severity
Score (NSS), a novel diagnostic tool with a functional status
assessment. We then evaluated the utility of the NSS, QST, and
other previously validated diagnostic tools in identifying patients
with moderate to severe peripheral neuropathy in a resource-
constrained setting.
Methods
The Kenya Medical Research Institute National Ethical Review
Committee and University of California San Francisco Committee
on Human Research approved this study. Written informed
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consent was obtained from a convenience sample of 30 HIV-
infected outpatients over 18 years of age between September and
October 2009 at Family AIDS Care and Education Services, an
HIV-care clinic in Kisumu, Kenya.
Nurses and clinical officers administered the diagnostic tool
under investigation (Appendix S1) to each participant. No training
was provided in its administration. The tool’s components were
derived from the Brief Peripheral Neuropathy Screen (Brief-PNS)
[3], Subjective Peripheral Neuropathy Screen (Subjective-PNS) [4],
Single Question Neuropathy Screen (Single-QNS) [5] and the phy-
sical function scale from the Medical Outcomes Study Core Survey
Instrument, RAND Health (www.rand.org/health/surveys_tool/
mos/). Scores for Brief-PNS, Subjective-PNS, Single-QNS, and
NSS (derived from Subjective-PNS and physical function scale)
were obtained (Appendix S2). The nurses and clinical officers
administering the tool were blinded to the neurologist’s assessment.
Study staff performed QST examination with monofilament[9,10],
graduated tuning fork [7,11–13], and two-point discriminator [8]
on each participant (Appendix S3). The order of QST examinations
was decided using a random number table. Study staff administer-
ing QST were blinded to the neurologist’s clinical assessment in all
but three cases where staffing constraints prevented blinded
administration. Eighteen different nurses and clinical officers were
used in the administration of the diagnostic tool; two different study
staff administered QST. Intra- and inter-observer variability for
QST examinations were not investigated in this study but have
been previously reported.[13–15]
A neurologist performed a standardized clinical assessment
based on AIDS Clinical Trials Group (ACTG) protocol.[16] The
neurologist was blinded to the results of the diagnostic tool, and, in
all but three cases mentioned above, blinded to the QST results.
Peripheral neuropathy was defined as the presence of $1 sign of
neuropathy - reduced sensation to pinprick, vibration, or reduced
ankle reflexes—definitions drawn from the ACTG protocol.[16]
For analysis, the study sample was dichotomized into moderate/
severe and mild/no peripheral neuropathy. Moderate peripheral
neuropathy was defined as pinprick diminished to the ankles or
vibration reduced to ,5 seconds at the great toe.
Demographic variables included mean household wealth,
calculated from self-report of household possessions, and food
insecurity, defined as eating #1 meal on any day in the week prior
to enrollment.
Statistical analyses were performed using Stata 10.0 (StataCorp,
College Station, Texas). Demographic and clinical characteristics
were compared using Fisher’s exact tests and t-tests. Diagnostic
utility of the screening tools and QST was determined using the
neurologist’s clinical assessment of moderate/severe neuropathy as
the gold standard. Sensitivity, specificity, predictive values,
likelihood ratios, and accuracy were calculated. Receiver operat-
ing characteristic (ROC) curves were generated for NSS,
Subjective-PNS, and two-point discrimination examinations.
Kappa statistic measured agreement on tool components assessed
by the neurologist and non-physician healthcare workers.
Results
The mean age of participants was 38.6 (610.5 SD) years, and 17
(57%) were male. A majority of patients were WHO Stage 3 or 4,
had CD4 counts ,350 cells/mL, and were currently taking
antiretroviral medications. Based on the neurologist’s gold standard
clinical examination, 16 (53%) of participants had neuropathy with
6 (20%) individuals havingmoderate or severe neuropathy (Table 1).
All participants with moderate/severe neuropathy had previously
used stavudine (d4T), and 2 (33%) were taking d4T at study
enrollment. Compared to those with mild/no neuropathy,
participants with moderate/severe neuropathy had significantly
lower mean household wealth and were significantly more likely to
have discontinued d4T due to neuropathy.
Diagnostic utility of the screening tools and QST in identifying
participants with moderate/severe neuropathy is presented in
Table 2. NSS and Subjective-PNS-max score performed identi-
cally and were the most specific, while Subjective-PNS-total had
the highest area under the ROC curve. Single-QNS was 83%
sensitive and 71% specific. Brief-PNS was 0% sensitive and 92%
specific. Agreement between ankle reflexes performed by non-
physician healthcare workers and by a neurologist was poor
(kappa= 0.04; 95% CI [20.19, 0.37]; p = 0.40). Monofilament
examination was 100% sensitive, 88% specific, and correctly
classified 90% of participants (Table 2). Tuning fork examination
was 83% sensitive and 88% specific while two-point discrimination
had a sensitivity of 75% and specificity of 58%.
Table 1. Comparison of demographic and clinical
characteristics between participants with mild or no
peripheral neuropathy and those with moderate or severe
peripheral neuropathy*.
None or
Mild
(n =24)
Moderate
or Severe
(n=6) p{
Age 37.5 (11.2) 43 (5.8) 0.26
Male 54% (13) 67% (4) 0.67
Household wealth (USD) { 888 (1384) 217 (97) 0.03
Food insecurity** 25% (6) 0% (0) 0.30
BMI 21.3 (2.8) 22.3 (3.6) 0.47
CD4 nadir 218 (158) 114 (74) 0.12
Current CD4 316 (229) 353 (126) 0.7
WHO Stage 3 or 4 54% (13) 83% (5) 0.36
Time since HIV diagnosis (months) 10.4 (0.88) 10.3 (0.52) 0.91
Ever used d4T 67% (16) 100% (6) 0.16
Current d4T use 46% (11) 33% (2) 0.67
Discontinued d4T due to peripheral
neuropathy
8% (2) 67% (4) 0.007
Ever used isoniazid 42% (10) 50% (3) 1.0
Ever used ddI 4% (1) 0% (0) 1.0
Any alcohol use 17% (4) 0% (0) 0.56
Abnormal thyroid exam 0% (0) 17% (1) 0.20
Mean corpuscular volume ever .100 fL 29% (7) 50% (3) 0.37
RPR ever positive 8% (2) 0% (0) 1.0
Random blood glucose ever .200 mg/dL 0% (0) 0% (0) ----
Fasting blood glucose ever .120 mg/dL 0% (0) 0% (0) ----
Creatinine ever .240 mmol/L (2.7 mg/dL) 0% (0) 0% (0) ----
ALT .80 U/L 0% (0) 0% (0) ----
Abbreviations: USD: United States Dollars; BMI: Body Mass Index; WHO: World
Health Organization; d4T: stavudine; ddI: didanosine; RPR: rapid plasma regain;
ALT: alanine transaminase.
*All variables presented as [mean (SD)] or [% (n)],
{p-values calculated from two-sample t-tests of means and of Fisher’s exact
tests of proportions.
{Household wealth calculated from patient self-report of household
possessions.
**Food insecurity defined as eating only 1 meal per day or having gone $1 day
without eating in the past one week.
doi:10.1371/journal.pone.0014256.t001
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Discussion
The overall prevalence of neuropathy in our sample was
comparable to previously published results from similar set-
tings.[5] While many previously established risk factors did not
differ significantly between participants with moderate/severe
neuropathy and those with mild/no neuropathy, mean household
wealth did. Mean household wealth may be a proxy measure for
another factor, such as nutritional status or the opportunity cost of
accessing medical care, including missed wages or transport costs.
Further investigation in a larger sample is warranted.
In our sample, NSS, Single-QNS, Subjective-PNS-total, and
Subjective-PNS-max performed well and had adequate sensitivity
and specificity to be useful as diagnostic tools in settings with high
neuropathy prevalence. Even Single-QNS, the simplest tool, had a
sensitivity over 80% and a specificity greater than 70%. A
Zambian study conducted by a different research group using
different methodology found Single-QNS was 96% sensitive and
80% specific.[5] These results provide support for routine use of
Single-QNS in resource-constrained settings.
NSS, which was developed to incorporate functional status
assessment into a diagnostic tool, did not improve gradation of
neuropathy severity as we anticipated. This may be due to small
sample size or insensitivity of the tool. Brief-PNS performed quite
poorly in our sample, (sensitivity = 0%), which is likely the result of
poor agreement of ankle reflexes between non-physician health-
care workers and the gold standard examination. Of note, we did
not provide training in evaluating ankle reflexes because our goal
was to identify a tool which would be feasible to scale up across
sub-Saharan Africa where such training would not often be
available.
Monofilament and graduated tuning fork also performed very
well and may be useful in research and selected clinical settings in
resource-constrained locations. QST offer objective measures of
neuropathy that are less expensive, necessitate less specialized
equipment, and require less training as compared to other
techniques such as nerve conduction studies. In addition, some
methods have been shown to predict health outcomes; for
example, monofilament examination has shown significant
predictive power in identifying individuals with neuropathy due
to diabetes and leprosy who are at greatest risk of experiencing
foot ulcerations.[6,17] However, these techniques must be
validated in resource-constrained settings to ensure feasibility
and accuracy.
This pilot study has several limitations. Prevalence estimates for
HIV-associated neuropathy should be interpreted with caution
due to small sample size, use of convenience sampling, and
inclusion of only outpatients enrolled in routine care. Additionally,
neuropathies identified in this population are likely due to both
HIV and other etiologies, as we were unable to definitively rule out
other causes. Finally, due to resource limitations, we were unable
to include other objective measures of neuropathy in our gold
standard, such as nerve conduction studies, computerized QST, or
intra-epidermal nerve fiber densities. Nerve conduction studies can
only be performed in Nairobi, Kenya, six to eight hours drive from
our study site. Computerized QST technology and intra-
epidermal nerve fiber densities are not currently available in
Kenya. Nevertheless, a neurologist’s clinical assessment has been
used widely in other studies and is an accepted gold standard [18].
A major strength of our study is its applicability to everyday
clinical practice in resource-constrained settings. Excluding QST,
we did not provide specialized equipment or training to non-
physician healthcare workers who administered the diagnostic
tools. As such, our results are likely replicable in similar resource-
constrained settings, so comparable results would be expected with
widespread implementation of these tools. However, these results
are preliminary and require further validation among a larger
sample before generalizing more broadly to other patient
populations.
Supporting Information
Appendix S1 Neuropathy Diagnostic Tool.
Found at: doi:10.1371/journal.pone.0014256.s001 (0.05 MB
DOC)
Appendix S2 Scoring of individual screening tools and quanti-
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Normative Values.
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Table 2. Diagnostic utility of peripheral neuropathy screening tools and quantitative sensory testing in detecting moderate to
severe peripheral neuropathy.
Sensitivity [95%CI] Specificity [95%CI] PPV NPV Acc LR+ LR- AUC Cutoff
Neuropathy Severity Score 66.7 [29, 104] 91.7 [81, 103] 66.7 91.7 86.7 8 0.4 0.83 $6
Subjective-PNS – Maximum Score 66.7 [29, 104] 91.7 [81, 103] 66.7 91.7 86.7 8 0.4 0.83 $5
Subjective-PNS) - Total Score 83.3 [53, 113] 83.3 [68, 98] 55.6 95.2 83.3 5 0.2 0.86 $6
Single Question Neuropathy Screen 83.3 [53, 113] 70.8 [53, 89] 41.7 94.4 73.3 2.9 0.2 0.77 ----
Brief-PNS 0 [0,0] 91.7 [81, 103] 0 78.6 73.3 0 1.1 0.46 ----
Monofilament 100 [100,100] 87.5 [74, 101] 66.7 100 90 8 0 0.94 $2
Graduated Tuning Fork 83.3 [53, 113] 87.5 [74, 101] 62.5 95.4 86.7 6.7 0.2 0.85 ----
Two-Point Discrimination 75 [40, 109] 58.3 [39, 78] 23.1 93.3 60.7 1.8 0.4 0.70 $4
Abbreviations: Acc: Accuracy; PNS: Peripheral Neuropathy Screen.
doi:10.1371/journal.pone.0014256.t002
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